Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

The 9 recipients receive $55,000 in seed money for collaborative projects that target one or more of the foundation’s strategic research goals.

Glaucoma Research Foundation announces 2025 recipients of Shaffer Research Grants

The study findings indicated that lifestyle changes associated with the COVID-19 pandemic were connected to an increase in childhood astigmatisms.

Researchers find significant increase in childhood astigmatism post-COVID

The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 of its ongoing phase 1 clinical trial of TH103 in treatment-naïve nAMD patients in the second half of 2025.

Kalaris and AlloVir Inc. complete merger

Intraoperative floppy iris syndrome is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery

Floppy iris syndrome risk: Study finds women more susceptible, key drugs identified

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

The FDA accepted for filing and granted Expedited Review status to Miravant   Medical Technologies' premarket application (PMA) for the IRIS Medical OcuLight   664 ophthalmic PDT laser.

Miravant PDT laser receives expedited review status